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Abstract
Background and Aims: The incidence of inflammatory bowel disease (IBD) is increasing in Eastern
Europe possibly due to changes in environmental factors towards a more “westernised” standard of
living. The aim of this study was to investigate differences in exposure to environmental factors
prior to diagnosis in Eastern and Western European IBD patients. 6Methods: The EpiCom cohort is a population-based, prospective inception cohort of 1560
unselected IBD patients from 31 European countries covering a background population of
10.1 million. At the time of diagnosis patients were asked to complete an 87-item questionnaire
concerning environmental factors.
Results: A total of 1182 patients (76%) answered the questionnaire, 444 (38%) had Crohn's
disease (CD), 627 (53%) ulcerative colitis (UC), and 111 (9%) IBD unclassified. No geographic
differences regarding smoking status, caffeine intake, use of oral contraceptives, or number of
first-degree relatives with IBD were found. Sugar intake was higher in CD and UC patients from
Eastern Europe than in Western Europe while fibre intake was lower (p b 0.01). Daily
consumption of fast food as well as appendectomy before the age of 20 was more frequent in
Eastern European than in Western European UC patients (p b 0.01). Eastern European CD and UC
patients had received more vaccinations and experienced fewer childhood infections than
Western European patients (p b 0.01).
Conclusions: In this European population-based inception cohort of unselected IBD patients,
Eastern and Western European patients differed in environmental factors prior to diagnosis.
Eastern European patients exhibited higher occurrences of suspected risk factors for IBD
included in the Western lifestyle.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
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 The occurrence of inflammatory bowel disease (IBD), Crohn's
disease (CD) and ulcerative colitis (UC) is increasing in Europe1
and across the rest of the world.2 Recent studies from Eastern
Europe3,4 have reported incidence rates comparable with
Western European countries; however, the overall regional
incidence of both CD and UC is twice as high inWestern Europe
as compared to Eastern Europe.5 Changes in lifestyle in
Eastern Europe during the last two decades have resulted in
a more “westernised” standard of living. Withmany aspects of
westernisation associated with a risk of IBD,6 such changes –
including an altered diet7,8 – could partly explain the observed
increases in the incidence of UC and CD in this geographic
region.
The European Crohn's and Colitis Organisation's (ECCO)
Epidemiological Committee (EpiCom) study is a prospective
population-based inception cohort of 1560 unselected IBD
patients diagnosed within 31 centres from Eastern and
Western Europe during 2010. In EpiCom-study it was shown
that incidence rates for CD and UC in Western European
centres are twice as high as in Eastern European centres.5
The aim of this study was to investigate differences in
exposure to environmental factors between Eastern and
Western European patients and whether these differences
could explain the observed incidence gradient. Further-
more, to investigate the possible influence of environmental
factors on disease presentation at diagnosis and disease
outcome within the first year. by guest on June 3, 2016
fordjournals.org/2. Materials and methods
2.1. Study population
During a one-year inclusion period from January 1st to
December 31st 2010, all incident IBD patients living in
predefined, well-described geographical areas were recruit-
ed from 31 centres in 8 Eastern and 14 Western European
countries in the EpiCom-cohort. A total number of 1560
adult and paediatric IBD patients were included out of a
total background population of 10.1 million inhabitants
(3.3 million in Eastern and 6.8 million in Western Europe).
Diagnostic criteria, time period of inclusion, recorded pa-
tient data, and ascertainment methods were standardised
and consistent.5 All incident patients were included and
followed-up carefully as previously described.5,9 Patients
aged b15 years at diagnosis were excluded from this paper.
2.2. Definitions and disease classifications
Patients were diagnosedwith CD, UC or IBD unclassified (IBDU)
according to the Copenhagen Diagnostic Criteria.10–12 Infec-
tious gastroenteritis, endamoeba and cancer had to be ruled
out in order to make the diagnosis. Patients who during
follow-up ended up with not having IBD were excluded from
the cohort. Disease classification of CD and UC regarding
extent, localization and behaviour was defined using the
Montreal Classification.13 Medical treatment was grouped
into five treatment groups of ascending potency of treat-
ment: 5-aminosalicylates (5-ASA) (oral and/or topical 5-ASA(oral steroids ± 5-ASA or topical steroids), immunomodulators
(azathioprine, 6-mercaptopurine, cyclosporine or methotrex-
ate ± steroids), biologicals (infliximab or adalimumab in
combination with any of the above), and surgery (major
abdominal surgery due to IBD regardless of medical treatment
prior to surgery). Immunomodulators were combined in one
category due to the fact that 94% of patients received
treatment with thiopurines. A severe disease course in UC
was defined as any disease extent and a need of high dose GCS
(0.5–1 mg/kg), and/or immunomodulators, and/or biologi-
cals, and/or surgery, while severe CD was defined as the
necessity for immunomodulators, and/or biologicals, and/or
surgery within the first year after diagnosis.2.3. Environmental factors questionnaire
Environmental factors prior to the development of IBD were
assessed using a questionnaire developed by the International
Organisation of Inflammatory Bowel Diseases (IOIBD). The
questionnaire consists of 87 questions covering 25 different
topics proposed to be environmental risk factors for CD and/
or UC and has previously been used in IBD cohorts14–16 and
evaluated in a case–control study.17 For statistical analysis
items were grouped into fourteen parameters: smoking status
at diagnosis, appendectomy before age 20, tonsillectomy
before age 20, use of oral contraceptives, breastfeeding during
infancy, childhood infections (measles, pertussis, rubella,
chickenpox, mumps, and/or scarlet fever), vaccinations (tu-
berculosis, pertussis, measles, rubella, diphtheria, tetanus,
and/or polio), high sugar consumption (≥2 of the following:
sugar in coffee, sugar in tea, daily intake of soft drinks, sugar on
breakfast cereals, sugar on porridge), high fibre intake (daily
intake of ≥3 of the following categories: fruit, vegetables,
wholemeal bread,≥4 pieces of bread, cornflakes,muesli), fast
food consumption, high intake of caffeine (≥2 cups of coffee or
tea per day), daily physical activity, access to running water at
home, and IBD in first-degree relatives.2.4. Data collection
Data regarding patient demographics and disease classifica-
tion at diagnosis, as well as medical therapy including
biological therapy, surgery, and hospitalizations, were col-
lected at time of diagnosis and prospectively throughout the
follow-up period. Validity of diagnostic and clinical data was
secured by a variety of measures as previously described5
including built-in control and validation tests, locked diagnos-
tic criteria in the database, manual data standardisation, and
random audits of case ascertainment and data quality at
participating centres showing good consistency with the
protocol. Patients were asked to complete the IOIBD
environmental factors questionnaire either by themselves
or, depending on educational level and whether local
translations of the questionnaire exist, during an interview
by the physician or IBD specialist trained nurses during an
outpatient visit. Data were entered by physicians and/or
IBD specialist trained nurses in the web-based EpiCom
database.18
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 2.5. Statistical analysis
Statistical analyses were performed using SAS software
version 9.2 (SAS Institute Inc., Cary, NC, USA). Demographics
and disease classification between groups were compared
with Chi-square test. The influence of environmental factors
for CD and UC patients from both regions combined on
disease classification at diagnosis, hospitalization, surgery,
biological therapy, severe disease course, extra-intestinal
manifestations at diagnosis, and highest treatment step
reached during follow-up was analysed using multivariate
logistic regression, while the impact on age of diagnosis was
analysed with simple multivariate linear regression. Gender,
age, and geographic region were included in the analysis,
together with disease classification, when relevant, as these
were considered confounding variables. Childhood infections
and vaccinations were excluded from the analysis as they
were highly correlated with year of birth. A p-value of b0.05
was considered statistically significant. Continuous variables
are expressed as median (range) unless otherwise stated.
2.6. Ethical considerations
The study was approved by the local ethical committees
according to local regulations. All patients gave written
informed consent prior to answering the questionnaires.
3. Results
3.1. Description of study population
In total, 1182 patients (76% of the original cohort) aged
15 years or older at diagnosis answered the questionnaire
after a median time of 1.1 months from diagnosis (range: 0–
16 months). Of these, 444 (38%) had CD, 627 (53%) UC, and
111 (9%) IBDU. A total of 249 (21%) patients came from
Eastern European centres while 933 (79%) patients came
from Western European centres. Patients' demographic
characteristics are presented in Table 1; no differences
were found between the geographic regions except for
highest treatment step reached during follow-up for CD and
UC patients. Of the 368 patients who did not answer the
questionnaire, 45 (4%) were b15 years at diagnosis and not
invited to participate in this study and 333 (96%) did not give
consent. Non-responding patients differed only in the
distribution of diagnosis (the fraction of CD patients was
larger and the fraction of IBDU patients was smaller
compared to responders), and in terms of extra-intestinal
manifestations (fewer patients had extra-intestinal mani-
festations compared to responders).
3.2. Environmental factors in European IBD patients
Occurrences of environmental factors in Western and Eastern
European IBD patients are shown in Table 2. Geographic
differences were found in terms of childhood vaccinations
(tuberculosis, pertussis,measles, rubella, diphtheria, and polio)
as significantly more CD and UC patients in Eastern Europe had
received vaccinations against these agents compared with
Western European patients (p b 0.01). Furthermore, for bothCD and UC more Western European patients had experienced
infections (measles, pertussis, and mumps) during childhood
(p b 0.01). Regarding dietary risk factors, more Western
European CD and UC patients reported high daily fibre intake
as well as low daily sugar intake (p b 0.01). More Eastern than
Western European UC patients had a daily consumption of fast
food (p b 0.01).
Multivariate linear regression revealed several factors
predicting age of diagnosis in CD and UC patients, shown in
Table 3. Significant environmental factors from logistic regres-
sion analysis predicting disease phenotype and extra-intestinal
manifestations at diagnosis, as well as surgery, hospitalization,
biological therapy, severe disease course, and treatment step
reached during follow-up are shown in Tables 4 and 5.
For CD patients disease behaviour was associated with risk
of surgery during the first year of disease (non-penetrating,
non-stricturing vs. penetrating disease: OR: 0.08, 95% CI: 0.03–
0.22; stricturing vs. penetrating OR: 1.0, 95% CI: 0.43–2.33), a
severe disease course (non-penetrating, non-stricturing vs.
penetrating disease: OR: 0.18, 95% CI: 0.08–0.44; stricturing
vs. penetrating OR: 0.86, 95% CI: 0.31–2.41), treatment step
(non-penetrating, non-stricturing vs. penetrating disease:
OR: 0.23, 95% CI: 0.13–0.42; stricturing vs. penetrating OR:
0.73, 95% CI: 0.37–1.43), and hospitalization (non-penetrating,
non-stricturing vs. penetrating disease: OR: 0.27, 95% CI: 0.14–
0.54; stricturing vs. penetrating OR: 0.89, 95% CI: 0.41–1.93).
In UC patients disease extent was associated with
hospitalization (proctitis vs. extensive colitis OR: 0.24, 95%
CI: 0.10–0.61; left-sided vs. extensive OR: 0.54, 95% CI:
0.31–0.95), biological therapy (proctitis vs. extensive colitis
OR: 0.11, 95% CI: 0.01–0.84; left-sided vs. extensive OR:
0.49, 95% CI: 0.21–1.11), severe disease course (proctitis vs.
extensive colitis OR: 0.14, 95% CI: 0.08–0.24; left-sided vs.
extensive OR: 0.42, 95% CI: 0.29–0.62), and treatment step
(proctitis vs. extensive colitis OR: 0.33, 95% CI: 0.21–0.54;
left-sided vs. extensive OR: 0.57, 95% CI: 0.40–0.81).4. Discussion
In this population-based inception cohort of unselected IBD
patients from Eastern and Western Europe we have shown
that patients in the geographic regions differ in terms of
environmental factors present prior to diagnosis. Eastern
European patients reported more vaccinations against tuber-
culosis, pertussis, measles, rubella, diphtheria, and polio, as
well as fewer childhood infections with measles, pertussis,
and mumps than Western European patients. Eastern Europe-
an CD patients consumed less fibre and more sugar than CD
patients in Western Europe. Daily fast food consumption was
more frequent in Eastern European than in Western European
UC patients.
The rapid increase in CD and UC incidence during the last
decades is unlikely to be explained by a change in genetic
susceptibility in the population alone. Westernisation of
lifestyle, including an increased consumption of refined
sugar, fatty acids, fast food, and reduced consumption of
fruit, vegetables and fibres,19 in the societies experiencing
an increasing occurrence of IBD may, at least in part, be
responsible for the recent changes20 as many aspects of a
western diet have been linked with a risk of IBD.21–24 The
substantial political and economic changes in countries from
Table 1 Patient characteristics of 1,182 incident patients from the ECCO-EpiCom cohort.
Western European centres Eastern European centres
CD UC IBDU CD UC IBDU
No. of patients (%) 345 (37%) 483 (52%) 105 (11%) 99 (40%) 144 (58%) 6 (2%)
Male (%) 181 (52%) 269 (56%) 51 (49%) 58 (59%) 82 (57%) 4 (67%)
Female (%) 164 (48%) 214 (44%) 54 (51%) 41 (41%) 62 (43%) 2 (33%)
Age at diagnosis, years 35 (16–89) 39 (15–89) 38 (17–79) 31 (15–78) 36 (18–81) 30 (20–34)
Time to diagnosis, months 4.6 (0–374) 2.5 (0–255) 2.5 (0–362) 3.3 (0–126) 2.2 (0–240) 2.7 (0–38)
First degree relative with IBD 34 (10%) 55 (11%) 18 (17%) 7 (7%) 10 (7%) 1 (17%)
Extra-intestinal complications
None 299 (87%) 436 (90%) 90 (86%) 83 (84%) 127 (88%) 5 (83%)
Skin 3 (1%) 6 (1%) 2 (2%) 2 (2%) 0 (0%) 0 (0%)
Eyes 4 (1%) 3 (1%) 2 (2%) 0 (0%) 1 (1%) 0 (0%)
Joints 33 (10%) 32 (7%) 8 (8%) 13 (13%) 12 (8%) 1 (17%)
Primary Sclerosing Cholangitis 0 (0%) 2 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%)
Pancreatitis 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%)
Other 4 (1%) 4 (1%) 3 (3%) 2 (2%) 1 (1%) 0 (0%)
Disease extent at diagnosis
E1: Proctitis 95 (20%) 29 (20%)
E2: Left-sided 204 (42%) 67 (47%)
E3: Extensive colitis 184 (38%) 48 (33%)
Disease location at diagnosis
L1: terminal ileum 101 (30%) 38 (39%)
L2: colonic 88 (26%) 20 (20%)
L3: ileo-colonic 79 (23%) 24 (24%)
L4: upper gastro-intestinal tract 25 (7%) 1 (1%)
L1+L4 22 (6%) 5 (5%)
L2+L4 10 (3%) 3 (3%)
L3+L4 16 (5%) 7 (7%)
Disease behaviour at diagnosis
B1: non-stricturing, non-penetrating 212 (61%) 67 (68%)
B2: stricturing 70 (20%) 19 (19%)
B3: penetrating 28 (8%) 5 (5%)
B1p: B1 + perianal 15 (4%) 1 (1%)
B2p: B2 + perianal 3 (1%) 0 (0%)
B3p: B3 + perianal 17 (5%) 7 (7%)
Highest treatment step reached during follow-up
0: No treatment 9 (3%) ⁎ 3 (1%) ⁎ 0 (0%) 0 (0%) 2 (1%) 0 (0%)
1: 5-ASA 46 (13%) ⁎ 236 (49%) ⁎ 50 (48%) 27 (27%) 88 (61%) 4 (67%)
2: GCS 58 (17%) ⁎ 127 (26%) ⁎ 30 (29%) 23 (23%) 34 (24%) 1 (17%)
3: Immunomodulators 117 (34%) ⁎ 80 (17%) ⁎ 12 (11%) 34 (34%) 17 (12%) 1 (17%)
4: Biological therapy 67 (19%) ⁎ 23 (5%) ⁎ 10 (10%) 5 (5%) 1 (1%) 0 (0%)
5: Surgery 48 (14%) ⁎ 14 (3%) ⁎ 3 (3%) 10 (10%) 2 (1%) 0 (0%)
⁎ Difference between geographic regions, pb0.05
611Environmental factors in the EpiCom-cohort
 by guest on June 3, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 the former Soviet Union have e.g. resulted in an increased
consumption of non-traditional, energy-dense processed
foods25,26 impacting on the risk of noncommunicable chronic
diseases in these countries.27 However, comparisons of dietary
habits in Eastern and Western European countries are sparse
and difficult to perform because of differences in methodol-
ogy.28 Dietary habits play an important role in shaping the
microbiota of the human gut,29 and a ‘Westernised’ diet is
hypothesized to alter the intestinal microbiota towards a
composition which increases the risk for the development of
IBD.8,30 However, most dietary studies have reported incon-
sistent findings regarding the role of dietary factors in the
development of IBD.31,32Previous studies have shown that a high consumption of
dietary fibre, fruits and vegetables is inversely associated
with the risk of CD.17,21,23,24 In the present study signifi-
cantly more Western European CD patients reported a high
daily intake of all three food groups prior to the diagnosis.
Additionally, more Eastern European CD and UC patients
reported a high daily intake of sugar, including soft drinks.
High daily sugar consumption was associated with an earlier
age of diagnosis in CD and was inversely associated with the
need for higher treatment steps during follow-up. Increased
sugar intake has previously been linked to the development
of CD14,23,31 and soft drink consumption has been proposed
as a possible risk factor for CD and UC,33 although overall
Table 2 Environmental factors prior to diagnosis in Eastern and Western European patients with inflammatory bowel disease.
Western Europe Eastern Europe
CD UC IBDU CD UC IBDU
Smoking status
Never 141 (42%) 262 (56%) 50 (51%) 36 (37%) 77 (53%) 4 (67%)
Currently 120 (36%) ⁎⁎ 38 (8%) 14 (14%) 37 (38%) ⁎⁎ 16 (11%) 2 (33%)
Former smoker 76 (23%) ⁎⁎ 168 (36%) 35 (35%) 25 (26%) ⁎⁎ 51 (35%) 0 (0%)
Breastfeeding 223 (65%) 307 (64%) 64 (61%) 68 (69%) 92 (64%) 4 (67%)
Tonsillectomy 62 (18%) 82 (17%) 16 (15%) 21 (21%) 26 (18%) 3 (50%)
Appendectomy 45 (13%) 45 (9%) ⁎ 6 (6%) 12 (12%) ⁎⁎ 3 (2%) 0 (0%)
Access to running water 312 (90%) 442 (92%) 90 (86%) 94 (95%) 126 (88%) 6 (100%)
Vaccinations:
Tuberculosis 175 (51%) ⁎ 270 (56%) ⁎ 57 (54%) 78 (79%) 105 (73%) 5 (83%)
Pertussis 159 (46%) ⁎ 217 (45%) ⁎ 51 (49%) 75 (76%) 94 (65%) 4 (67%)
Measles 185 (54%) ⁎ 236 (49%) ⁎ 46 (44%) 67 (68%) 89 (62%) 5 (83%)
Rubella 177 (51%) ⁎ 226 (47%) 39 (37%) 63 (64%) 75 (52%) 3 (50%)
Diphtheria 184 (53%) ⁎ ⁎⁎ 292 (60%) ⁎ 63 (60%) 75 (76%) 108 (75%) 5 (83%)
Tetanus 244 (71%) 361 (75%) 80 (76%) 79 (80%) 99 (69%) 4 (67%)
Polio 209 (61%) ⁎ ⁎⁎ 342 (71%) 73 (70%) 73 (74%) 108 (75%) 4 (67%)
Childhood infections
Measles 109 (32%) ⁎ 178 (37%) ⁎ 45 (43%) 14 (14%) 28 (19%) 0 (0%)
Pertussis 39 (11%) ⁎ 51 (11%) ⁎ 13 (12%) 1 (1%) 3 (2%) 0 (0%)
Rubella 82 (24%) 116 (24%) 26 (25%) 21 (21%) 26 (18%) 1 (17%)
Chicken pox 219 (63%) 319 (66%) 60 (57%) 68 (69%) 89 (62%) 5 (83%)
Mumps 64 (19%) ⁎⁎ 131 (27%) ⁎ 33 (31%) 21 (21%) 23 (16%) 1 (17%)
Scarlet fever 32 (9%) 56 (12%) 7 (7%) 8 (8%) 10 (7%) 0 (0%)
Fruit daily 185 (54%) ⁎ 265 (55%) 57 (54%) 39 (39%) 67 (47%) 2 (33%)
Vegetables daily 204 (59%) ⁎ 287 (59%) 70 (67%) 41 (41%) ⁎⁎ 79 (55%) 2 (33%)
Bread (≥4 slices/day) 159 (46%) 220 (46%) ⁎ 39 (37%) 49 (49%) 84 (58%) 3 (50%)
Eggs daily 24 (7%) 43 (9%) ⁎ 95 (90%) 13 (13%) 27 (19%) 1 (17%)
Muesli daily 28 (8%) 52 (11%) ⁎ 12 (11%) 6 (6%) 5 (3%) 0 (0%)
Cornflakes daily 41 (12%) ⁎ 39 (8%) 7 (7%) 5 (5%) 7 (5%) 0 (0%)
High fibre intake 148 (43%) ⁎ 223 (46%) ⁎ 57 (54%) 25 (25%) 48 (33%) 1 (17%)
High sugar intake 160 (46%) ⁎ ⁎⁎ 188 (39%) ⁎ 36 (34%) 63 (64%) 99 (69%) 2 (33%)
Soft drink daily 80 (23%) ⁎ ⁎⁎ 82 (17%) ⁎ 14 (13%) ⁎ 47 (47%) 68 (47%) 4 (67%)
Fast food daily 30 (9%) 33 (7%) ⁎ 4 (4%) ⁎ 10 (10%) 20 (14%) 3 (50%)
Juice daily 100 (29%) 131 (27%) 23 (22%) 21 (21%) 39 (27%) 3 (50%)
Coffee (≥2 cups/day) 126 (37%) ⁎ 206 (43%) ⁎ 39 (37%) 25 (25%) 39 (27%) 2 (33%)
Tea (≥2 cups/day) 95 (28%) ⁎ 128 (27%) ⁎ 29 (28%) 43 (43%) 73 (51%) 4 (67%)
Caffeine 182 (53%) 275 (57%) 56 (53%) 53 (54%) 81 (56%) 4 (67%)
Oral contraceptive use 49 (30%) 52 (24%) 11 (20%) 11 (27%) ⁎⁎ 6 (10%) 1 (50%)
Daily physical activity 102 (30%) 176 (36%) 39 (37%) 39 (39%) 57 (40%) 3 (50%)
⁎ Difference between geographic regions, p b 0.05.
⁎⁎ Difference between Crohn's disease and ulcerative colitis patients, p b 0.05.
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 evidence is inconsistent and subject to important method-
ological limitations such as the lack of prospective studies.34
Furthermore, the question remains whether the high sugar
intake is in fact a consequence of CD symptoms and patients
are simply trying to counteract weight loss or fatigue.35
Overall, incidence rates for CD and UC were in this cohort
found to be twice as high in Western Europe than in Eastern
Europe,5 but it would seem that Eastern European patients
are exposed to a greater number of risk factors – some who
have been confirmed in a Danish population-based inception
cohort17 – prior to diagnosis than Western European patients,
thus supporting the hypothesis of Western diet as part of the
explanation for the increasing incidence. However, due to the
lack of a control group in this study the true impact of dietaryhabits in disease risk needs to be confirmed in further
prospective studies. Also, since no previous study on the diet
of Eastern European IBD patients pre-diagnosis is available for
comparison we are not able to assess the changes in diet over
time.
In a Swedish population-based case control study the
consumption of fast food was associated with an increased
risk of CD and UC.36 In the present study more Eastern
European than Western European patients reported daily
consumption of fast food among those with UC but not CD,
and daily consumption of fast food was associated with
young age at diagnosis in both CD and UC as well as increased
risk for surgery and severe disease extent in UC patients.
Additionally, the proportion of patients reporting a high
Table 3 Factors predicting a young age at diagnosis for
patients with Crohn's disease (CD) and ulcerative colitis
(UC) in a European inception cohort.
CD UC
Male gender p = 0.034 –
Current smoker p = 0.004 –
Previous smoker – p b 0.001
Ever smoked p b 0.001 –
No tonsillectomy b 20 yr – p = 0.013
No appendectomy b 20 yr p = 0.002 p b 0.001
Breastfeeding during infancy – p = 0.014
Running water at home p b 0.001 p b 0.001
Oral contraceptives p b 0.001 p b 0.001
High sugar intake consumption p = 0.006 –
Low daily caffeine intake – p b 0.001
Daily fast food consumption p b 0.001 p b 0.001
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 caffeine intake was similar in both geographic regions for CD
and UC, but high caffeine consumption was associated with
the risk of surgery and a severe disease course during
follow-up in CD and with the presence of extra-intestinal
manifestations at diagnosis in UC patients. However, high
caffeine intakewas also inversely associatedwith young age at
diagnosis. This is in conflict with other studies that mostly did
not find a relationship between caffeine and IBD.37 Whether
fast food and caffeine directly influence the risk and course of
IBD or are surrogate markers for e.g. psychological stress38,39
or a higher consumption of bacteria in food remains to be
proven.
The risk of CD and UC has consistently been reported to
be increased by the use of oral contraceptives,40 with the
mechanism hypothesized to be multifocal, microvascular
gastrointestinal infarctions.41 In the present study the use of
oral contraceptives was significantly associated with a young
age at diagnosis. This conclusion, however, is biased due toTable 4 Environmental factors and Crohn's disease patients' su
biological therapy, severe disease course, extra-intestinal manif
inception cohort.
Hospitalization Surgery Biological
therapy
Se
co
Age at diagnosis,
per year
– – 0.98
(0.96–1.0)
0.
(0
Being Eastern
European
– – 0.11
(0.03–0.36)
0.
(0
Current smoking – – – –
High intake of
caffeine
– 2.18
(1.01–4.71)
– 1.
(1
Appendectomy – – 0.25
(0.07–0.83)
0.
(0
High daily sugar
intake
– – – 0.
Breastfeeding
during infancy
– – – –the lack of a control group. Patients in this cohort are young
and a high frequency of oral contraceptive use is expected.
Furthermore, oral contraceptives in UC were inversely
associated with requiring the highest necessary treatment
step during follow-up as well as severe disease extent at
diagnosis. The influence of oral contraceptives on disease
course in IBD patients remains unclear.42,43 However, a
Danish inception cohort study found a similar relationship
between use of oral contraception and disease localisation
of UC.15
Appendectomy is thought to be inversely associated with
the development of UC.44,45 In this cohort significantly more
Western than Eastern European UC patients reported an
appendectomy before the age of 20. Additionally, in Eastern
Europe more CD patients had an appendectomy prior to
diagnosis than UC patients, in accordance with a Danish
population-based cohort.15 The association of appendecto-
my with CD is still unclear.46 Interestingly, appendectomy
decreased the odds of a severe disease course in CD patients
as well as the need for biological therapy, whereas others
have reported a worsened disease course.47 Appendectomy
was inversely associated with young age at diagnosis, in
accordance with a previous Australian study.48 No difference
in the occurrence of breastfeeding during infancy between
Eastern and Western Europe was found. Breastfeeding is
thought to have a protective effect against CD and UC.49 In
this study we could not confirm this observation, since
breastfeeding during infancy was found to be associated
with young age at diagnosis as well as with the risk of
presenting with extra-intestinal manifestations at diagnosis
in CD.
In terms of childhood infections and vaccinations we
observed significant geographic differences in both CD and UC
patients. Vaccinations against tuberculosis, pertussis, measles,
rubella, diphtheria, and polio occurred more frequently, while
childhood infections with measles, pertussis, and mumps had
occurred less frequently in Eastern European CD and UC
patients compared to Western European patients. It has been
hypothesized that a lack of exposures to enteric pathogensbsequent risk (odds ratio, 95% CI) of hospitalization, surgery,
estations, high treatment step, and behaviour in a European
vere disease
urse
Extra-intestinal
manifestations
Treatment
step
Disease
behaviour
97
.96–0.99)
– 0.98
(0.97–0.99)
–
33
.19–0.58)
– 0.37
(0.23–0.60)
–
– – 1.59
(1.03–2.44)
86
.15–2.99)
– 1.84
(1.24–2.72)
–
34
.17–0.66)
– 0.48
(0.27–0.86)
–
53 (0.33–0.86) – – –
2.34 (1.17–4.67) – –
e 3, 2016
Table 5 Environmental factors and ulcerative colitis patients' subsequent risk (odds ratio, 95% CI) of hospitalization, surgery,
biological therapy, severe disease course, extra-intestinal manifestations, high treatment step, and extent in a European
inception cohort.
Hospitalization Surgery Biological
therapy
Severe disease
course
Extra-intestinal
manifestations
Treatment
step
Disease
Extent
Age at diagnosis,
per year
0.98
(0.96–1.0)
– 0.95
(0.92–1.0)
0.99
(0.98–1.0)
– – –
Female vs. male – – – – 2.14
(1.25–3.68)
– 0.68
(0.49–0.95)
Being Eastern
European
0.31
(0.14–0.69)
– 0.08
(0.01–0.62)
0.55
(0.36–0.84)
– 0.43
(0.29–0.64)
–
IBD in 1st degree
relatives
0.29
(0.09–0.95)
– – – 2.22
(1.10–4.51)
– 1.76
(1.07–2.89)
Never smoked – – 2.86
(1.21–6.75)
– – – –
Oral contraceptive – – – – – 0.51
(0.29–0.92)
0.56
(0.33–0.98)
Daily fast food
intake
– 5.78
(1.88–17.76)
– – – – 2.03
(1.17–3.52)
High intake of
caffeine
– – – – 2.86
(1.55–5.26)
0.67
(0.50–0.95)
–
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 during childhood is a risk factor for CD especially50,51 and that
multiple childhood infections and poor hygiene are protective
against IBD.52 In light of this hypothesis one could suggest that
Eastern European patients in this cohort carried a risk for
developing IBD due to more vaccinations and fewer infections
during childhood, however, the observed differences could be
skewed by recall bias. Furthermore, studies have focused on
specific infectious agents like paromyxoviral infection and
vaccination with inconsistent findings.53–55 In this study the
prevalence of childhood infections and vaccinations was highly
correlated with year of birth, as the vaccination pattern
apparently has changed during the lifetime of the patients
included. Therefore only age at diagnosis was included in the
analysis.
Finally, the impact of smoking on the risk and severity of
CD and UC has been thoroughly investigated. Active smoking
is a risk factor for developing CD while being protective
against UC.56,57 In accordance with this, in both regions
more CD patients than UC patients were current smokers at
diagnosis, while more UC than CD patients were previously
smokers. The frequency of smokers and former smokers
was similar to estimations from the European Union.58
Current smoking at diagnosis was positively associated
with more severe disease behaviour and young age at
diagnosis in CD, while previous smoking was associated
with young age at diagnosis in UC patients. UC patients
who had never smoked prior to diagnosis had higher odds
of needing biological therapy during the first year of
disease.
The primary strength of this study was that the EpiCom
cohort is population-based, that patients were prospectively
included and followed up, and that the cohort consists of
unselected IBD patients thus representing the broad spec-
trum of disease from mild to severe cases. Data quality and
validity as well as consistency between centres were
ensured by various measures described elsewhere.5 Further-
more, a short duration from onset of symptoms to diagnosis,5as well as the fact that patients answered the questionnaire
very close to the date of diagnosis to some extent reduced
the risk of recall bias concerning e.g. dietary habits prior to
the IBD diagnosis. However, a number of important limita-
tions need to be considered. The IOIBD questionnaire,
although previously used,14–17 has never been validated or,
to our knowledge, properly forward/backward translated
into languages other than English. Because of the cost of
such a validation and translation process and since the IOIBD
questionnaire was constructed by an expert group and never
tested in other specialist group, patients or IBD nurses it was
decided in the EpiCom-group not to include a validation in
the protocol. Also, in this study if patients were not able to
fill out the questionnaire by themselves the doctor or IBD
specialist nurse completed the questionnaire together with
the patient and this could have introduced bias in the
results. Questions regarding factors from early life such as
vaccinations and infections are most likely subject to
reporting and recall bias, while questions regarding dietary
factors could be biased by misclassifications by the patients.
Furthermore, some questions in the questionnaire are broad
and might not capture the intended exposure of the
environmental factor. Also, by including this large number
of risk factors in the analysis, some associations found might
be due to chance alone. Additionally, the study is limited by
the fact that information on regional dietary habits and
vaccination status was unavailable in several participating
centres and a comparison of dietary habits between IBD
patients and the background population therefore was not
possible. Last and most important, since no control group
was included in this study it remains to be investigated
whether environmental factors influencing the IBD patients
in this cohort differ from the background population, and
the associations with disease presentation and course need
to be further investigated.
To conclude, in this population-based inception cohort of
unselected IBD patients from Eastern and Western Europe the
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 geographic regions differed in terms of environmental factors
prior to diagnosis. The observed differences could not explain
the West–East gradient in IBD incidence in Europe, but Eastern
European patients exhibited higher occurrences of suspected
risk factors included in theWestern lifestyle for IBD, which lends
support to the theory of Westernisation of lifestyle having a
main role in the recent increases in IBD incidence in Eastern
Europe. However, these findings demand further investigation
through controlled trials.
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